English | 简体中文 | 繁體中文 | 한국어
Share:
Pulmocide Limited: Pulmocide Raises $30 Million in Series B Financing
Pulmocide Limited: Pulmocide Raises $30 Million in Series B Financing

http://pulmocide.com/wp-content/themes/wordpress-bootstrap/images/pulmocide-logo.gif

Pulmocide Raises $30 Million in Series B Financing

Funding to progress novel wholly-owned compounds for RSV and pulmonary Aspergillosis

London, UK, 20 March 2017: Pulmocide Ltd, the UK-based drug discovery company developing novel compounds designed for inhaled delivery to treat respiratory syncytial virus (RSV) and pulmonary aspergillosis, today announced the completion of a $30.4 million Series B financing round. The round was led by new investor SR One and included Longwood Fund plus existing investors SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation - JJDC, Inc. and Touchstone Innovations plc.

The proceeds will enable Pulmocide to progress its wholly-owned assets through early clinical development.  Pulmocide is on track to deliver proof of concept data in RSV with its highly potent inhaled RSV antiviral agent (PC786) in human RSV challenge and in infants hospitalised with bronchiolitis due to RSV infection.

Pulmocide will also be progressing PC945, a potent azole antifungal for the treatment of pulmonary Aspergillosis, including fungal asthma, pulmonary Aspergilloma, Aspergillus infections in lung transplant recipients and patients with cystic fibrosis.

Dr Garth Rapeport, Chief Executive Officer of Pulmocide, commented: "Respiratory infections are a significant cause of global morbidity and mortality with a high unmet medical need. Pulmocide is developing bespoke inhaled medicines to provide effective and safe therapies for the treatment of RSV and pulmonary Aspergillosis.

"This Series B fundraising will provide us with the capital to advance our two novel compounds through early clinical development; another step closer to a treatment for patients for these debilitating infections. We are delighted by the interest we've received in this round and would like to thank our new and existing shareholders for their support and continued commitment to Pulmocide.  We look forward to providing further pipeline updates as developments progress with our important programmes."

Matthew Foy, Partner at SR One, added: "Pulmocide's core asset is the management team's proprietary expertise in the design of highly potent compounds with extended lung retention time and limited systemic exposure. This has enabled the development of two anti-infective drugs for serious diseases of the lung, where an inhaled therapy should deliver the optimal clinical outcome. SR One is excited to be joining such a strong syndicate of investors to support Pulmocide as it progresses both programmes towards clinical proof of concept."

- Ends -

For further information, please contact:

Pulmocide Ltd
Garth Rapeport, Chief Executive Officer
+44 203 763 9484
[email protected]

Consilium Strategic Communications
Mary-Jane Elliott, Ivar Milligan
+44 20 3709 5702
[email protected]

About Pulmocide:
Pulmocide is a privately-held company located in London, developing novel small molecule inhaled medicines for the treatment of life threatening respiratory infections caused by RSV and Aspergillus. The development of potent anti-infective agents with optimal characteristics for lung delivery is highly attractive from a safety and efficacy perspective with the avoidance of systemic liability. This approach offers the prospect of a new generation of safe and tolerated inhaled therapies for patients in areas of high unmet clinical need. Pulmocide's investors include SR One, SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation - JJDC, Inc., Touchstone Innovations plc and Longwood Fund. For more information please visit www.pulmocide.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Pulmocide Limited via Globenewswire

Copyright © Thomson Reuters 2017. All rights reserved.
 Subscribe RSS Feed  
Press Releases
TS GNW EU IRI integration test  
Mar 25, 2017 06:45 ET
Update on HEINEKEN Acquisition of Punch Taverns Portfolio  
Mar 24, 2017 17:01 ET
ObsEva SA to Attend Needham Annual Healthcare Conference in NYC  
Mar 24, 2017 17:00 ET
ASM INTERNATIONAL N.V. ANNOUNCES REQUEST BY EMINENCE CAPITAL TO INCLUDE DISCUSSION ITEM ON 2017 AGM AGENDA  
Mar 24, 2017 15:52 ET
Nets A/S: Nets A/S announces fixed income investor meetings for potential notes offering by its subsidiary Nassa Topco AS  
Mar 24, 2017 14:04 ET
Lubrizol Breaks Ground on Polyisobutylene Unit in Deer Park, Texas  
Mar 24, 2017 03:03 ET
NANOBIOTIX: the Independent Data Monitoring Committee recommends the continuation of the ongoing phase II/III trial of NBTXR3 in Soft Tissue Sarcoma  
Mar 24, 2017 01:23 ET
Lubrizol to Increase Its Equity in Lubrizol India Private Limited  
Mar 20, 2017 21:03 ET
Pulmocide Limited: Pulmocide Raises $30 Million in Series B Financing  
Mar 20, 2017 15:03 ET
Sequa Petroleum N.V. commences liquidation of its 100% Norwegian subsidiary (Tellus)  
Mar 17, 2017 15:03 ET
More News >>
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: